Presentation Authors: Gregory C. McMahon*, Sravan Panuganti, Michael Wilson, Kiran Thalody, Stratford, NJ, Thomas J. Mueller, Voorhees, NJ
Introduction: Benign prostatic hyperplasia (BPH) with associated lower urinary tract symptoms (LUTS) has a significant impact on quality of life. Multi-institutional projects have demonstrated Prostatic urethral lift (PUL) as a minimally invasive procedure with strong 5-year durability, minimal side effect profile, and no associated erectile or ejaculatory dysfunction. Long term single series data are needed. This studies purpose was to report on, to our knowledge, the largest single surgeon series of PUL.
Methods: We completed a retrospective chart review of men who underwent PUL in the office from June 2016 to May 2018. PUL, also known as Urolift (NeoTract, Pleasanton, CA, USA), was performed in the office by a single surgeon. International prostatic symptom score (IPSS), quality of life (QOL), and post void residuals (PVR) were recorded at baseline and at subsequent office visits. A paired-samples T-test was used to compare pre and post treatment values.
Results: We identified 156 men who had undergone a PUL. Descriptive statistics demonstrated an average age of 69Â± 11.9, prostate volume of 53.9 Â± 29.1, number of implants used 5.5 Â± 0.9, and post-operative catheter duration of 1.6 Â± 1.8 days. When comparing IPSS, QOL, and PVR 151, 142, and 116 paired samples were available and the mean follow up period was 7.6 Â± 5.8 [Range 0.5-24] months. IPSS values improved significantly 65% from 18.9 Â± 7.4 to 6.7 Â± 5.0 (-12.2 Â± 7.7 p < 0.05). QOL improved significantly 59% from 4.1 Â± 1.3 to 1.7 Â± 1.3 (-2.4 Â± 1.7 p < 0.05). Similarly, PVR decreased significantly 58% from 153.1 Â± 232.8 to 64.2 Â± 125.4 (-88.9 Â± 150.6 p < 0.05).
Conclusions: To our knowledge, this is the largest single surgeon series reported on PUL. Our data demonstrated statistically significant improvement in IPSS 65%, QOL 59%, and PVR 58% at an average of 7.6 months. As our data set matures we hope to externally validate prior studies as well as report on patient group previous excluded from PUL, including patients in urinary retention, prostate volumes < 30 or >80 grams, and having prior prostate interventions.